CA2538737A1 - Treatment of respiratory diseases with anti-il-2 receptor antibodies - Google Patents

Treatment of respiratory diseases with anti-il-2 receptor antibodies Download PDF

Info

Publication number
CA2538737A1
CA2538737A1 CA002538737A CA2538737A CA2538737A1 CA 2538737 A1 CA2538737 A1 CA 2538737A1 CA 002538737 A CA002538737 A CA 002538737A CA 2538737 A CA2538737 A CA 2538737A CA 2538737 A1 CA2538737 A1 CA 2538737A1
Authority
CA
Canada
Prior art keywords
antibody
daclizumab
asthma
patients
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002538737A
Other languages
English (en)
French (fr)
Inventor
Richard S. Shames
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PDL Biopharma Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2538737A1 publication Critical patent/CA2538737A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
CA002538737A 2003-09-23 2004-09-21 Treatment of respiratory diseases with anti-il-2 receptor antibodies Abandoned CA2538737A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US50588303P 2003-09-23 2003-09-23
US60/505,883 2003-09-23
US55297404P 2004-03-12 2004-03-12
US60/552,974 2004-03-12
PCT/US2004/031640 WO2005030252A1 (en) 2003-09-23 2004-09-21 Treatment of respiratory diseases with anti-il-2 receptor antibodies

Publications (1)

Publication Number Publication Date
CA2538737A1 true CA2538737A1 (en) 2005-04-07

Family

ID=34396276

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002538737A Abandoned CA2538737A1 (en) 2003-09-23 2004-09-21 Treatment of respiratory diseases with anti-il-2 receptor antibodies

Country Status (8)

Country Link
US (1) US20050089517A1 (enExample)
EP (1) EP1675615A1 (enExample)
JP (1) JP2007506681A (enExample)
AU (1) AU2004275860A1 (enExample)
BR (1) BRPI0414688A (enExample)
CA (1) CA2538737A1 (enExample)
RU (1) RU2006113701A (enExample)
WO (1) WO2005030252A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7932365B2 (en) 2003-11-08 2011-04-26 Pro Thera Biologics, Llc Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
JP5793076B2 (ja) 2008-05-28 2015-10-14 プロセラ バイオロジクス， インコーポレイテッド 血液由来インター−アルファ−阻害タンパク質の調製及び組成物。
AU2009325088B2 (en) * 2008-12-10 2014-06-19 Duke University Inhibition of inter-alpha trypsin inhibitor for the treatment of airway disease
EP2710384B1 (en) * 2011-05-12 2017-11-08 Temple University - Of The Commonwealth System of Higher Education Diagnosis and treatment of copd
US9572872B2 (en) 2012-09-09 2017-02-21 Prothera Biologics, Inc. Treatment of disease using inter-alpha inhibitor proteins
CA3036553A1 (en) 2016-09-13 2018-03-22 Prothera Biologics, Inc. Methods for treating pulmonary disease using inter-alpha inhibitor proteins
CN110177564A (zh) 2016-12-13 2019-08-27 德里尼亚公司 多价的调节t细胞调节剂
KR102587810B1 (ko) 2017-04-25 2023-10-11 프로테라 바이오로직스, 인크. 인터-알파 억제제 단백질을 정량화하는 방법
WO2020140040A1 (en) * 2018-12-29 2020-07-02 Kaleo, Inc. Devices and methods for delivery of substances within a prefilled syringe
CN114641283B (zh) * 2019-10-04 2024-07-12 R.P.谢勒技术有限责任公司 抗cd25抗体-美登素偶联物及其使用方法
US12268847B1 (en) 2021-02-10 2025-04-08 Kaleo, Inc. Devices and methods for delivery of substances within a medicament container
GB202106254D0 (en) * 2021-04-30 2021-06-16 Teva Uk Ltd Inhaler system
CN118370816A (zh) * 2024-03-22 2024-07-23 中日友好医院(中日友好临床医学研究所) Il-2/抗il-2抗体免疫复合物的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4473493A (en) * 1981-04-29 1984-09-25 Immunex Corporation Hybridoma antibody which inhibits interleukin 2 activity
US4411993A (en) * 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US4845198A (en) * 1984-05-21 1989-07-04 Immunex Corporation Hybridoma antibody which binds IL-2 receptor
US5336489A (en) * 1985-09-05 1994-08-09 The Beth Israel Hospital Association Treatment of allograft rejection with IL-2 receptor-specific cytotoxins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1992008474A2 (en) * 1990-11-20 1992-05-29 The National Heart & Lung Institute Treatment of lung diseases
MX9707862A (es) * 1995-04-14 1997-11-29 Glaxo Wellcome Inc Inhalador de dosis medida para el propionato de fluticasona.
US6013256A (en) * 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
DE69937057T2 (de) * 1998-07-27 2008-05-29 Novartis Ag Verwendung von basiliximab zur behandlung von rheumatoider arthritis und hauterkrankungen
WO2002081508A2 (en) * 2001-04-06 2002-10-17 University Of Bristol Use of cd25 binding molecules in steroid-resistant patients
AU2003295471B2 (en) * 2002-11-15 2011-08-25 Genmab A/S Human monoclonal antibodies against CD25

Also Published As

Publication number Publication date
JP2007506681A (ja) 2007-03-22
RU2006113701A (ru) 2007-11-10
BRPI0414688A (pt) 2006-11-28
WO2005030252A1 (en) 2005-04-07
EP1675615A1 (en) 2006-07-05
AU2004275860A1 (en) 2005-04-07
US20050089517A1 (en) 2005-04-28

Similar Documents

Publication Publication Date Title
JP7695298B2 (ja) Ｉｌ－４ｒ拮抗薬の投与により喘息を処置または予防するための方法
JP7665098B2 (ja) 多重特異性抗体およびその使用
RU2752785C2 (ru) Применение антагонистов il-13 для лечения атопического дерматита
EP2888281B1 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
TW202304980A (zh) 經修飾的抗ｔｓｌｐ抗體
SG11202111255YA (en) Methods for treating or preventing asthma by administering an il-33 antagonist
US20050089517A1 (en) Treatment of respiratory diseases with anti-IL-2 receptor antibodies
JP2024542777A (ja) 多発血管炎、好酸球増多症候群、好酸球増多症候群、鼻ポリープを伴う慢性副鼻腔炎（ｃｒｓｗｎｐ）又は鼻ポリープを伴わない慢性副鼻腔炎（ｃｒｓｓｎｐ）の処置における使用のためのインターロイキン５結合タンパク質投与レジメン
JP2024500912A (ja) インターロイキン５結合タンパク質の投与レジメン
KR20220066295A (ko) 항트립타제 항체의 투약
US12583929B2 (en) Method of treating acute respiratory distress syndrome
JP7668943B2 (ja) 多重特異性抗体およびその使用
RU2861706C2 (ru) Мультиспецифические антитела и их применение
MXPA06003129A (en) Treatment of respiratory diseases with anti-il-2 receptor antibodies
CN116635417A (zh) 白介素5结合蛋白给药方案
CN1856325A (zh) 用抗il－2受体的抗体治疗呼吸道疾病
HK40107894A (en) Methods for treating or preventing asthma by administering an il-4r antagonist
HK40119918A (en) Multispecific antibodies and uses thereof
WO2025226628A1 (en) Use of il-6 inhibitors for preventing or inhibiting lung transplantation rejection in a subject
WO2022136209A1 (en) Interleukin 5 binding protein dosage regimen
HK40007968A (en) Uses of il-13 antagonists for treating atopic dermatitis
HK1225303A1 (en) Methods for improving asthma symptoms using benralizumab
HK1225303B (en) Methods for improving asthma symptoms using benralizumab
HK1211605B (en) Methods for treating or preventing asthma by administering an il-4r antagonist
WO2021243396A1 (en) Therapeutic methods of using cd 14 antagonistic antibodies in treating conditions associated with a coronavirus infection including sars-cov-2 (covid-19)

Legal Events

Date Code Title Description
FZDE Discontinued